Results 191 to 200 of about 87,925 (315)

Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party

HemaSphere, Volume 9, Issue 4, April 2025.
Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) remains a curative treatment for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) in their first complete remission (CR1). Recent results using the combination of blinatumomab and second‐ or third‐generation tyrosine kinase inhibitors have challenged ...
Ali Bazarbachi, Myriam Labopin, Iman Abou Dalle, Ibrahim Yakoub‐Agha, Gérard Socié, Thomas Schroeder, Didier Blaise, Xavier Poiré, Marie Balsat, Urpu Salmenniemi, Nicolaus Kröger, Alexander Kulagin, Eva Maria Wagner‐Drouet, Depei Wu, Eolia Brissot, Arnon Nagler, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty   +18 more
wiley   +1 more source

New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib. [PDF]

Arch Endocrinol Metab
Salimova D, Aloyan T, Qureshi U, Qureshi F, Wazir H.   +4 more
europepmc   +1 more source

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy [PDF]

, 2003
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman, Heather C. Flynn, Sarah F. Paternoster, Brandon M. Shearer, Terra L. Reeder, Chin‐Yang Li, Nicholas C.P. Cross, Jan Cools, D. Gary Gilliland, Gordon W. Dewald, Ayalew Tefferi   +12 more
openalex   +1 more source

Frequency and Characteristics of Gastrointestinal Diseases in Patients With Neurofibromatosis

JGH Open, Volume 9, Issue 4, April 2025.
ABSTRACT Background and Aim Patients with neurofibromatosis (NF) frequently experience gastrointestinal symptoms, but the specific characteristics of these lesions are not well understood. Methods To investigate the prevalence and nature of gastrointestinal diseases in this population, we analyzed the gastrointestinal lesions identified through ...
Manami Honda, Masaya Iwamuro, Takehiro Tanaka, Yasushi Yamasaki, Seiji Kawano, Sakiko Hiraoka, Yoshiro Kawahara, Motoyuki Otsuka   +7 more
wiley   +1 more source

Further Insight Found into Molecular Basis for Imatinib Resistance in CML

, 2002
Peggy Peck
openalex   +1 more source

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells [PDF]

, 2003
Su Chu, Melissa Holtz, Mamta Gupta, Ravi Bhatia   +3 more
openalex   +1 more source

A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia. [PDF]

Cell Commun Signal
Bica V, Venafra V, Massacci G, Graziosi S, Gualdi S, Minnella G, Sorà F, Chiusolo P, Brunetti ME, Napolitano G, Breccia M, Mougiakakos D, Böttcher M, Fischer T, Perfetto L, Sacco F.   +15 more
europepmc   +1 more source

Imatinib Superior to Standard Therapy in Newly Diagnosed CML

, 2002
Lilian Delmonte
openalex   +1 more source

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome [PDF]

, 2003
Jorge E. Cortés, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William G. Wierda, Mary Beth Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop M. Kantarjian   +9 more
openalex   +1 more source

Lymphocytic Variant Hypereosinophilic Syndrome: Case Series From a Tertiary Referral Center in Canada

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Background Lymphocytic variant hypereosinophilic syndrome (L‐HES) is a rare disorder characterized by persistent eosinophilia driven by aberrant T‐cell populations. Diagnosis remains challenging due to the lack of standardized diagnostic criteria.
Xiu Qing Wang, Kevin Shopsowitz, Jack Lofroth, Xuehai Wang, Erica Peterson, Andrew P. Weng, Luke Y. C. Chen   +6 more
wiley   +1 more source